Výsledky vyhledávání - "Suzette Warren"

Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial

Autor: Rajiv Agarwal, Patrick Rossignol, Bryan Williams, Alain Romero, Martha Mayo, William B. White, Jia Ma, Suzette Warren, Dahlia Garza

Publikováno v: The Lancet. 394:1540-1550

Summary Background Spironolactone is effective at reducing blood pressure in patients with uncontrolled resistant hypertension. However, the use of spironolactone in patients with chronic kidney disease can be restricted by hyperkalaemia. We evaluate

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::209a6a5c2084f25349d54060ab1dfb19
https://doi.org/10.1016/s0140-6736(19)32135-x

Zobrazit plný text záznamu

Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): results in the pre-specified subgroup with heart failure

Autor: Patrick Rossignol, Rajiv Agarwal, Gail Ackourey, William B. White, Susan Arthur, Bryan Williams, Martha Mayo, Suzette Warren

Publikováno v: European Journal of Heart Failure
European Journal of Heart Failure, 2020, 22 (8), pp.1462-1471. ⟨10.1002/ejhf.1860⟩
European Journal of Heart Failure, Oxford University Press (OUP), 2020, 22 (8), pp.1462-1471. ⟨10.1002/ejhf.1860⟩

International audience; Aims: The AMBER trial demonstrated that concomitant use of patiromer enabled the more persistent use of spironolactone by reducing the risk of hyperkalaemia in patients with resistant hypertension and advanced chronic kidney d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::118c043ac093b6ae18c0caf7b27618d5
https://hal.univ-lorraine.fr/hal-03020061/document

Zobrazit plný text záznamu

Patiromer to Enable Spironolactone Use in the Treatment of Patients with Resistant Hypertension and Chronic Kidney Disease: Rationale and Design of the AMBER Study

Autor: Bryan Williams, Rajiv Agarwal, Alain Romero, Martha Mayo, Dahlia Garza, Suzette Warren, Susan Arthur, Patrick Rossignol, William B. White

Publikováno v: American Journal of Nephrology. 48:172-180

Background: While chronic kidney disease (CKD) is common in resistant hypertension (RHTN), prior studies evaluating mineralocorticoid receptor antagonists excluded patients with reduced kidney function due to risk of hyperkalemia. AMBER (ClinicalTr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e958dfd401f6c3b46a75ca67c5e4c94
https://doi.org/10.1159/000492622

Zobrazit plný text záznamu

Effects of the Potassium-Binding Polymer Patiromer on Markers of Mineral Metabolism

Autor: David Spiegel, Pablo E. Pergola, David A. Bushinsky, Suzette Warren, Jinwei Yuan, Jeanene Fogli

BACKGROUND AND OBJECTIVES: Patiromer is a sodium-free, nonabsorbed, potassium-binding polymer that uses calcium as the counter-exchange ion and is approved for treatment of hyperkalemia. The 4-week TOURMALINE study in patients with hyperkalemia previ

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67c2c8fa4849a3cd0fb0de5ca70d1ed9
https://europepmc.org/articles/PMC6364526/

Zobrazit plný text záznamu

Patiromer Lowers Serum Potassium When Taken without Food: Comparison to Dosing with Food from an Open-Label, Randomized, Parallel Group Hyperkalemia Study

Autor: David Spiegel, Jinwei Yuan, Pablo E. Pergola, Matthew R. Weir, Suzette Warren

Background: Patiromer is a sodium-free, nonabsorbed, potassium binder approved for treatment of hyperkalemia. This open-label study compares the efficacy and safety of patiromer administered without food versus with food. Methods: Adults with hyperka

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3ba963adb239706a657e4eb8f1a273e
https://europepmc.org/articles/PMC5804834/

Zobrazit plný text záznamu

Patiromer vs. Placebo to Enable Spironolactone in Patients with Resistant Hypertension and Chronic Kidney Disease (AMBER): Results in Prespecified Subgroups

Autor: Bryan Williams, Rajiv Agarwal, Jia Ma, Patrick Rossignol, Suzette Warren, William B. White, Gail Ackourey, Dahlia Garza, Martha Mayo

Publikováno v: Journal of Cardiac Failure. 25:939

Introduction Spironolactone (SPIRO) is effective at reducing blood pressure (BP) in patients (pts) with uncontrolled resistant hypertension (RHTN); however, its use in pts with chronic kidney disease (CKD) may be limited by hyperkalemia. Hypothesis R

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a465f53c0f52790c82b961b3b4351b79
https://doi.org/10.1016/j.cardfail.2019.11.010

Zobrazit plný text záznamu

Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial

Autor: Bertram, Pitt, Stefan D, Anker, David A, Bushinsky, Dalane W, Kitzman, Faiez, Zannad, I-Zu, Huang, Suzette, Warren

Publikováno v: European Heart Journal. 32:820-828

To evaluate efficacy and safety of RLY5016 (a non-absorbed, orally administered, potassium [K+]-binding polymer) on serum K+ levels in patients with chronic heart failure (HF) receiving standard therapy and spironolactone.One hundred and five patient

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0bdbdae3c5f383d22eee6e37a8f5237
https://doi.org/10.1093/eurheartj/ehq502

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání